Your Board stands firmly behind Datascope's management team and strategy. We are extremely excited about our new products, R&D pipeline, and the operating changes being implemented by our senior management team. At the same time, your Board remains committed to returning excess capital to shareholders. Your Board recommends that all shareholders support this team by voting FOR James Loughlin and William Asmundson on the BLUE proxy card today.
Datascope is moving forward vigorously with its plans to increase
shareholder value and drive sustainable and profitable growth. Key elements
of Datascope's strategic plan include:
-- Strengthening our senior management team. In October 2007, Datascope
promoted Dr. Antonino Laudani to the newly-established role of Chief
-- Continued expansion of our innovative product portfolio. In early
October 2007, Datascope launched NetGuard(TM), our revolutionary new
Clinical Alert System. Datascope conservatively estimates the market
potential for NetGuard to be in excess of $1 billion in annual sales in
the U.S. alone.
-- In addition to introducing nine new patient monitoring products in
2007, our new Sensation(TM) 7 Fr. fiber-optic balloon catheter and the
CS300 intra aortic balloon pump (IABP) underscore Datascope's
leadership position in the Cardiac Assist market.
-- Continued investment in Research & Development. Investment in R&D is
critical to Datascope's continued growth and success. We are committed
to continuing to invest in R&D and have a number of exciting new
products in the pipeline.
-- Focusing on growing our core businesses. In October 2006, after
thorough analysis, your Board and senior management determined to exit
the interventional products market. We also est
|SOURCE Datascope Corp.|
Copyright©2007 PR Newswire.
All rights reserved